Large granular lymphocytic leukemia (LGLL) is a rare lymphoproliferative disorder of transformed natural killer or T-cells attributed to chronic exposure to the proinflammatory cytokine IL-15. Diagnosis of the majority of T-cell LGLL is established by documenting clonal large granular lymphocytes (LGLs) in peripheral blood, by morphology and immunophenotype. The proteasome inhibitor bortezomib is known to target molecular pathways downstream of the IL-15 receptor signaling and has been proposed as a therapy in these patients. We report an uncommon presentation of LGLL with chronic neutropenia lacking typical blood LGLs, which failed to respond to bortezomib but obtained a very good partial remission with a classical methotrexate regimen.
CITATION STYLE
Bagacean, C., Tempescul, A., Patiu, M., Fetica, B., Bumbea, H., & Zdrenghea, M. (2017). Atypical aleukemic presentation of large granular lymphocytic leukemia: A case report. OncoTargets and Therapy, 10, 31–34. https://doi.org/10.2147/OTT.S115892
Mendeley helps you to discover research relevant for your work.